During the corresponding time, Maxcyte Inc saw a revenue deteriorated by -14.53 % year on year, sequentially revenue fell by -24.66 %. While revenue at the Maxcyte Inc 's corporate clients
Maxcyte Inc's Comment on Sales, Marketing and Customers
The company serves a diverse customer base that includes leading commercial cell therapy drug and biologic developers, major biopharmaceutical companies, academic and government research institutions such as the U.S. National Institutes of Health (NIH), and 32 SPL customers. Its clientele comprises a majority of the top 25 pharmaceutical companies by 2024 global revenue, as well as hundreds of biotechnology companies and academic centers focused on translational research. The company's Flow Electroporation® technology was utilized by one SPL customer to engineer the first ex vivo cell therapy approved by the FDA in December 2023. The acquisition of SeQure Dx expands the company's capabilities to support ex vivo and in vivo cell and gene therapy developers, offering tools and services that cover early research and development through clinical development and commercialization.
Revolutionizing Cellular Therapy: MaxCyte and Ori Biotech’s Game-Changing CollaborationIn the fast-paced world of biotechnological innovation, where the stakes are as high as the potential benefits, the partnership between MaxCyte and Ori Biotech emerges as a beacon of transformative potential. With the convergence of advanced platforms, cutting-edge technology, and strategic vision, this collaboration stands to significantly reshape the landscape of autologous cellular therapies. MaxCyte, a front-runner in cell engineering, and Ori Biotech, renowned for its technological prowess in manufacturing platforms for cell and gene therapies, have joined forces in a visionary partnership. Their mutual ambition: t...
MaxCyte Partners with Be Biopharma to Advance Engineered B Cell MedicinesMaxCyte, a leading biotechnology company, has recently announced a strategic platform license agreement with Be Biopharma, a pioneering player in the field of Engineered B Cell Medicines (BCMs). This collaboration aims to propel the development and production of BCMs by leveraging MaxCyte s cutting-edge Flow Electroporation technology and ExPERT platform.Under this agreement, Be Biopharma will deploy MaxCyte s innovative Flow Electroporation technology and ExPERT platform across its Engineered B Cell Medicines programs. These programs focus on harnessing the power of the body s own immune system to treat a wide range of diseases, includ...
MaxCyte and Wugen Partner to Accelerate Manufacturing of Cell Therapies for Cancer TreatmentMaxCyte Inc. and Wugen Inc. have recently announced a strategic platform license agreement aimed at expediting the scale-up of clinical and commercial manufacturing of Wugen s investigational allogeneic, off-the-shelf cell therapies for hematologic and solid tumor cancers. Under this agreement, Wugen will utilize MaxCyte s Flow Electroporation technology and ExPERT platform to support its programs in developing advanced therapies for cancer treatment.Wugen, a biotechnology company specializing in the development of allogeneic cell therapies, aims to revolutionize cancer treatment by providing off-the-shelf, readily av...
Maxcyte Inc’s Comment on Sales, Marketing and Customers
The company serves a diverse customer base that includes leading commercial cell therapy drug and biologic developers, major biopharmaceutical companies, academic and government research institutions such as the U.S. National Institutes of Health (NIH), and 32 SPL customers. Its clientele comprises a majority of the top 25 pharmaceutical companies by 2024 global revenue, as well as hundreds of biotechnology companies and academic centers focused on translational research. The company's Flow Electroporation® technology was utilized by one SPL customer to engineer the first ex vivo cell therapy approved by the FDA in December 2023. The acquisition of SeQure Dx expands the company's capabilities to support ex vivo and in vivo cell and gene therapy developers, offering tools and services that cover early research and development through clinical development and commercialization.
Sources:
Maxcyte inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Maxcyte inc’s corporate clients.
For your research, we’ve provided 9 tables on Maxcyte inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
106.41 %